Clinical Trial Update: Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg [Phase 3]

View source ↗

Summary

Phase 3 study evaluating LACTEOL 340 mg for diarrhea-predominant irritable bowel syndrome was terminated, with results posted on 2013-12-30.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diarrhea-predominant Irritable Bowel Syndrome

Drugs mentioned

• LACTEOL 340 mg

Snippet

Sponsor: Forest Laboratories | Conditions: Diarrhea-predominant Irritable Bowel Syndrome | Phase 3 | Status: TERMINATED | Results posted: 2013-12-30